[
  {
    "ts": "2025-10-18T16:12:51+00:00",
    "headline": "What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders",
    "summary": "Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-phase-3-oncology-161251252.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "478a85de-40ca-3e87-a4d8-9475b2904d97",
      "content": {
        "id": "478a85de-40ca-3e87-a4d8-9475b2904d97",
        "contentType": "STORY",
        "title": "What Pfizer (PFE)'s Phase 3 Oncology Advances Mean for Shareholders",
        "description": "",
        "summary": "Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...",
        "pubDate": "2025-10-18T16:12:51Z",
        "displayTime": "2025-10-18T16:12:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-phase-3-oncology-161251252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-phase-3-oncology-161251252.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-18T14:30:40+00:00",
    "headline": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
    "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
    "url": "https://www.investors.com/news/technology/bladder-cancer-padcev-keytruda-merck-pfizer-astellas/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "fc57e9fe-46ee-3e3d-9136-49fc2f129aaf",
      "content": {
        "id": "fc57e9fe-46ee-3e3d-9136-49fc2f129aaf",
        "contentType": "STORY",
        "title": "Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients",
        "description": "",
        "summary": "Pharma titans Merck, Pfizer and Astellas Pharma are delivering an \"enormous new hope\" for patients with an aggressive form of bladder cancer.",
        "pubDate": "2025-10-18T14:30:40Z",
        "displayTime": "2025-10-18T14:30:40Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/fc57e9fe-46ee-3e3d-9136-49fc2f129aaf/pfizer-merck-and-astellas.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xSQ8YwM67Zr8eoVxIL10wg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/inbcP9SXCOD3CuYclH_fcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/cc1ba840394999bd8d2f9e90faab7a81.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/bladder-cancer-padcev-keytruda-merck-pfizer-astellas/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "4503.T"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-18T14:30:00+00:00",
    "headline": "PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer",
    "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based",
    "url": "https://finance.yahoo.com/news/padcev-plus-keytruda-given-surgery-143000336.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "f1a3075f-f38f-3641-a1e7-0fde59ffe35f",
      "content": {
        "id": "f1a3075f-f38f-3641-a1e7-0fde59ffe35f",
        "contentType": "STORY",
        "title": "PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer",
        "description": "",
        "summary": "Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based",
        "pubDate": "2025-10-18T14:30:00Z",
        "displayTime": "2025-10-18T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/538cc2b9d8ecb50adbc09b44a523e1dc",
          "originalWidth": 400,
          "originalHeight": 97,
          "caption": "Pfizer | Astellas",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CQ1ItBH.MhqUOsqSOWqmIA--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/538cc2b9d8ecb50adbc09b44a523e1dc.cf.webp",
              "width": 400,
              "height": 97,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vsCnjsrqzvCLhjtrpW0AKg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/538cc2b9d8ecb50adbc09b44a523e1dc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/padcev-plus-keytruda-given-surgery-143000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/padcev-plus-keytruda-given-surgery-143000336.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALPMF"
            },
            {
              "symbol": "ALPMY"
            },
            {
              "symbol": "4503.T"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]